Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +83.79%
#3 Seeker Seeker +72.11%
#4 AI XOVIA AI XOVIA +52.42%
#5 UnifAI Network UnifAI Network +33.65%
#6 Pons Pons +30.52%
#7 Tensor Tensor +26.60%
#8 TENDIES TENDIES +25.33%
#9 pipedog pipedog +22.04%
#10 Zylo Ecosystem Zylo Ecosystem +21.96%
Coin of the day
Helium Helium
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Ergomed plc Ergomed plc

Ergomed plc

2EM
Rangering i aksjer #11481
Ergomed plc, alongside its affiliated entities, offers a comprehensive range of... Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.
Aksjekurs
$13.05
Sist synkronisert: 2023-03-31
Markedsverdi
$695.07M
Endring (1 dag)
4.59%
Endring (1 år)
0.00%
Land
GB
Handel Ergomed plc (2EM)

Kategori

Healthcare
P/E-forhold for Ergomed plc (2EM)
P/E-forhold per 2026 TTM: 0
Ifølge Ergomed plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Ergomed plc fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.